Remote Ischemic Conditioning in Pediatric Cancer Patients Receiving Anthracycline Chemotherapy: A Sham-Controlled Single-Blind Randomized Trial
Authors' conclusion
RIC did not exhibit cardioprotective effects in childhood cancer patients receiving anthracycline-based chemotherapy.
Study context
- Population
- Pediatric cancer patients receiving anthracycline-based chemotherapy
- Participants
- 68 patients
- Comparison
- Remote ischemic conditioning (RIC) vs sham intervention
- RICn = 34
- Shamn = 34reference
- Primary endpoint
- Plasma high-sensitivity cardiac troponin T (hs-cTnT) level
Methodological detailsphase 2, sham-controlled, single-blind
- Phase 2
- Sham-controlled
- Single-blind
Primary result
As reported in the abstract
Plasma hs-cTnT
- Progressive increase across time points in RIC
- P < 0.001
- Progressive increase across time points in sham
- P < 0.001
- No significant differences between groups at each time point
- all P > 0.05
Secondary outcomes
LV tissue Doppler and strain parameters
- No significant differences between groups at each time point
- all P > 0.05
Safety
- No patients developed HF or cardiac arrhythmias
Original publication
Remote Ischemic Conditioning in Pediatric Cancer Patients Receiving Anthracycline Chemotherapy: A Sham-Controlled Single-Blind Randomized Trial. JACC CardioOncol. Published 21 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →